ArticleBMC public health2017
Active surveillance study of adverse events following immunisation of children in the Czech Republic.
Article in BMC public health, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 39 citations in OpenAlex.
- Active surveillance of immunization adverse effects: a multicentre, open-label, three-arm randomized uncontrolled trial in Ethiopia.International health · 2025Trial
- Comparison of active versus passive surveillance adverse event reporting in a paediatric ambulatory chiropractic care setting: a cluster randomised controlled trial.BMJ open quality · 2020Trial
- Perception of healthcare administrators on the impediments of optimizing adverse events following immunization e-Reporting in Nigeria.PloS one · 2025Article
- System and facility readiness assessment for conducting active surveillance of adverse events following immunization in Addis Ababa, Ethiopia.International health · 2023Article
- Documenting capacity and existing gaps in reporting adverse events following immunisation in Northern Ghana: a quantitative cross-sectional survey of healthcare workers.BMJ public health · 2023Article
- Myocarditis and Pericarditis Post-mRNA COVID-19 Vaccination: Insights from a Pharmacovigilance Perspective.Journal of clinical medicine · 2023Article
- The Impact of a Revised National Childhood Immunization Schedule on Vaccination Defaulters.Vaccines · 2023Article
- Article
- Evaluation of the adverse events following immunization surveillance system, Ghana, 2019.PloS one · 2022Article
- Article
- Article
- Immune-Mediated Disease Flares or New-Onset Disease in 27 Subjects Following mRNA/DNA SARS-CoV-2 Vaccination.Vaccines · 2021Article
- Parental Declaration of Adverse Event Following Immunization in a Cross-Sectional Study in Poland.International journal of environmental research and public health · 2019Article
- Article
- Adverse events following immunisation (AEFI) reports from the Zimbabwe expanded programme on immunisation (ZEPI): an analysis of spontaneous reports in Vigibase® from 1997 to 2017.BMC public health · 2019Article
- Use of routinely collected electronic healthcare data for postlicensure vaccine safety signal detection: a systematic review.BMJ global health · 2019Article
- Vaccines Safety in Children and in General Population: A Pharmacovigilance Study on Adverse Events Following Anti-Infective Vaccination in Italy.Frontiers in pharmacology · 2019Article
- Comparative Assessment of the Incidence of Fever among Prophylactic Acetaminophen-Treated and Non-Treated Infants after Pentavalent Vaccine in a Tertiary Institution in Abakaliki, Southeast Nigeria.Nigerian medical journal : journal of the Nigeria Medical AssociationArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDespite the undisputed public health benefits of routine vaccination, adverse events following immunisation (AEFI) remain a concern. As most adverse events are mild, they may be under-reported; this may underlie the wide range of AEFI rates reported in the literature. We investigated the rates of AEFI related to routine vaccination of children 0-10 years old in the Czech Republic.
methodsThe study reviewed patients' records in a sample of 49 paediatric GP practices covering all 12 administrative regions of the Czech Republic between 2011 and 2013. Adverse events following routine immunisation of children aged 0-10 years were identified and recorded.
resultsThe overall rate of AEFI was 209/100,000 doses; this was 6 times higher than the rate reported to the Czech State Institute for Drug Control (34/100,000 doses). Over two fifths (44%) of all AEFI occurred after the booster dose of the combined diphteria, tetanus and pertussis vaccine in 5-year old children. The vast majority of AEFI were non-serious local events (e.g. redness) and fever. Most AEFI occurred the second day after the immunisation, lasted 4 days on average, and were treated by cold therapy, antipyretics and analgesics.
conclusionsThe rate of AEFI identified in this study was considerably higher than the officially reported rate. Although the vast majority of AEFI were non-serious, health care providers and the public should be educated and encouraged to report AEFI to address the issue of underreporting, to increase the safety profile of vaccines, and to improve public confidence in immunisation programmes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.